Abstract
The nigrostriatal dopaminergic pathway was selected as a model system to determine the form (i.e., type A or B) of monoamine oxidase (MAO) present within central dopamine (DA)-containing neurons. The preferential accumulation and subsequent intraneuronal deamination of [14C]DA by striatal synaptosomes was examined in synaptosomal-rich homogenates obtained from rats previously treated (i.v.) with graded doses of either clorgyline or deprenyl. To confirm the selective MAO inhibitor properties of clorgyline or deprenyl, type A and B MAO activity was simultaneously assayed in striatal aliquots of the same tissue pool. The selective inhibition of type A MAO by clorgyline was associated wih a decline in the synaptosomal deamination of [14C]DA. These results were further substantiated by experiments performed on the synaptosomal deamination of [3H]DA, newly synthetized from [3H]tyrosine in the presence of either clorgyline or deprenyl. The deamination of newly synthetized [3H]DA was reduced by the selective inhibition of type A MAO. Finally, the destruction of DA-containing nigrostriatal neurons by the stereotaxic administration of 6-hydroxydopamine produced a selective reduction in the type A MAO activity in the striatum ipsilateral to the 6-hydroxydopamine-injected substantia nigra. A high correlation was obtained between the size of the DA-containing neuronal lesion and the reduction in type A MAO activity. No reduction in type B MAO activity was observed. These results strongly indicate the presence of the type A form of MAO within nigrostriatal dopaminergic neurons of the rat brain.
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|